Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in
combination with standard gemcitabine as first-line treatment for patients with metastatic
pancreatic cancer.